Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva

• Status: Not yet recruiting
• Trial end date: 2022-12-16
• Target enrollment: 0
• Participant gender: All

Summary

This project will develop and assess the feasibility and acceptability of a salive-based assay to monitor adherence to Mass Drug Administration (MDA) campaigns within Soil-transmitted helminthiasis (STH) control programs, evaluating the salive and serum pharmacokinetics of ALBENDAZOLE (ABZ) and its metabolites.The final goal is to obtain a field ready tool for the measurement of adherence to anthelmintic treatment at a community level that serves as a coverage/adherence indicator and a reference standard for other monitoring tools.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Universidad Nacional de Salta
• Collaborator: Fundacion Mundo Sano
• Treatments: Albendazole

Criteria

Inclusion Criteria:

Body Mass Index: 18 to 25.

Physical exam without significant abnormal findings.

Exclusion Criteria:

Pregnancy

Lactation

Use of ABZ or other benzimidazole drugs in the previous 30 days

History of intolerance to ABZ

Malabsorption and/or other gastrointestinal conditions that might compromise ABZ absorption.